Key facts
- 16.5% of Gen Z adults in South Korea used GLP-1 obesity drugs in 2025.
- Overall usage rate for GLP-1 obesity drugs in South Korea was 10.3% in 2025.
- Appearance management was the top reason for GLP-1 drug use among Gen Z.
- Health improvement was the top reason for GLP-1 drug use among Baby Boomers.
- 57.3% of respondents are concerned about the side effects of obesity treatments.
Roughly one in six Gen Z adults in South Korea used or were prescribed GLP-1 slimming drugs in 2025, according to the 2026 Korea Wellness Report released by KB Financial Group. The survey of 2,000 adults aged 25 to 69 found an overall uptake of 10.3% for these medications. Gen Z, born from 1995 onward, showed the highest usage rate at 16.5%, significantly higher than older generations. Appearance and body shape management was the primary driver for Gen Z's use, contrasting with health improvement cited by Baby Boomers. Concerns about side effects were prevalent, with over half of respondents expressing worry.